-+ 0.00%
-+ 0.00%
-+ 0.00%

Pliant presents updated Phase 1 PLN-101095 data in ICI-refractory solid tumors

PUBT·04/18/2026 17:31:19
Listen to the news
Pliant presents updated Phase 1 PLN-101095 data in ICI-refractory solid tumors
  • Pliant presented updated Phase 1 dose-escalation data for PLN-101095 with pembrolizumab at AACR 2026, covering results through Feb. 27, 2026.
  • Trial showed signs of anti-tumor activity in heavily pretreated patients with immune checkpoint inhibitor-refractory solid tumors, with responses strengthening over time.
  • Safety profile remained broadly manageable, with few treatment stops tied to side effects.
  • Company started a Phase 1b indication-expansion study in NSCLC, high tumor mutational burden tumors, clear cell renal cell carcinoma, with interim data expected in 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pliant Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604181331PRIMZONEFULLFEED9692490) on April 18, 2026, and is solely responsible for the information contained therein.